EA200500615A1 - Модуляция тревоги через блокаду гидролиза анандамида - Google Patents
Модуляция тревоги через блокаду гидролиза анандамидаInfo
- Publication number
- EA200500615A1 EA200500615A1 EA200500615A EA200500615A EA200500615A1 EA 200500615 A1 EA200500615 A1 EA 200500615A1 EA 200500615 A EA200500615 A EA 200500615A EA 200500615 A EA200500615 A EA 200500615A EA 200500615 A1 EA200500615 A1 EA 200500615A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- substituted
- unsubstituted
- heteroaryl
- group
- disorders
- Prior art date
Links
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 title 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 title 1
- 230000007062 hydrolysis Effects 0.000 title 1
- 238000006460 hydrolysis reaction Methods 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 biphenylyl Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Описываются ингибиторы гидролазы амидов жирных кислот формулы (I), где X представляет собой NH, CH, O или S; Q представляет собой O или S; Z представляет собой O или N, R представляет собой ароматическую группу, выбранную из группы, состоящей из замещенного или незамещенного арила, замещенного или незамещенного бифенилила, замещенного или незамещенного нафтила и замещенного или незамещенного фенила, замещенного или незамещенного терфенелила, замещенного или незамещенного циклоалкила, гетероарила или алкила; и Rи Rвыбирают независимо из группы, состоящей из H, замещенного или незамещенного алкила, замещенного или незамещенного гетероалкила и замещенного или незамещенного фенила, замещенного или незамещенного бифенилила, замещенного или незамещенного арила и замещенного или незамещенного гетероарила; при условии, что если Z представляет собой O, один из Rи Rотсутствует; и что, если Z представляет собой N, необязательно Rи Rмогут быть взяты вместе с образованием замещенного или незамещенного N-гетероцикла или замещенного или незамещенного гетероарила с атомом N, к которому присоединяется каждый из них. Описываются фармацевтические композиции, содержащие соединения формулы (I), и способы их применения для ингибирования FAAH и/или для лечения расстройств аппетита, глаукомы, боли, бессонницы и неврологических и психических расстройств, включая расстройства тревоги, эпилепсию и депрессию.Отчет о международном поиске был опубликован 2004.07.29.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41700802P | 2002-10-07 | 2002-10-07 | |
PCT/US2003/031844 WO2004033422A2 (en) | 2002-10-07 | 2003-10-07 | Modulation of anxiety through blockade of anandamide hydrolysis |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200500615A1 true EA200500615A1 (ru) | 2005-10-27 |
EA010267B1 EA010267B1 (ru) | 2008-06-30 |
Family
ID=32093946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500615A EA010267B1 (ru) | 2002-10-07 | 2003-10-07 | Модуляция тревоги через блокаду гидролиза анандамида |
Country Status (11)
Country | Link |
---|---|
US (3) | US7176201B2 (ru) |
EP (1) | EP1558591B1 (ru) |
JP (1) | JP4515911B2 (ru) |
KR (1) | KR20050088992A (ru) |
CN (1) | CN100408556C (ru) |
AU (1) | AU2003279877B2 (ru) |
CA (1) | CA2501506C (ru) |
EA (1) | EA010267B1 (ru) |
MX (1) | MXPA05003715A (ru) |
UA (1) | UA80841C2 (ru) |
WO (1) | WO2004033422A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2693457C2 (ru) * | 2013-07-18 | 2019-07-03 | Фондацьоне Иституто Итальяно Ди Текнолоджия | Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9923738D0 (en) * | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
AU2002311784B2 (en) * | 2001-03-29 | 2007-11-22 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
WO2004034968A2 (en) * | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Combination therapy for controlling appetites |
UA80841C2 (en) * | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
EP1608319A4 (en) * | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
WO2005089380A2 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
CA2542547A1 (en) * | 2003-10-16 | 2005-05-26 | Daniele Piomelli | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
ES2319213T3 (es) * | 2004-06-23 | 2009-05-05 | F. Hoffmann-La Roche Ag | Inhibidores de mao-b. |
US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
WO2006045119A2 (en) * | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
KR100693528B1 (ko) * | 2004-10-29 | 2007-03-14 | 주식회사 팬택 | 전원 지연 인가 기능을 가지는 무선통신 단말기 |
MX2007006178A (es) * | 2004-11-23 | 2007-06-20 | Ptc Therapeutics Inc | Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular. |
KR101063663B1 (ko) * | 2005-02-17 | 2011-09-07 | 아스텔라스세이야쿠 가부시키가이샤 | 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 |
WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
WO2007061862A2 (en) * | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
US20070155707A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
EP1969051A2 (en) * | 2005-12-29 | 2008-09-17 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
WO2007106706A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders |
US20100292266A1 (en) * | 2006-05-26 | 2010-11-18 | Richard Apodaca | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase |
EP2054055A2 (en) * | 2006-08-18 | 2009-05-06 | N.V. Organon | Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
US7888394B2 (en) | 2006-08-21 | 2011-02-15 | N.V. Organon | Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors |
US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
WO2008030752A2 (en) * | 2006-09-07 | 2008-03-13 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
US20090099240A1 (en) * | 2006-10-02 | 2009-04-16 | N.V. Organon | Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
WO2008063714A1 (en) * | 2006-11-20 | 2008-05-29 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
WO2008100977A2 (en) * | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
DE102007022007A1 (de) * | 2007-05-08 | 2008-11-13 | Schebo Biotech Ag | Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes |
JP5406828B2 (ja) * | 2007-05-25 | 2014-02-05 | ザ スクリプス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼの四環式阻害剤 |
CA2689148A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
CN102209718A (zh) | 2008-11-06 | 2011-10-05 | 安斯泰来制药株式会社 | 氨基甲酸酯化合物或其盐 |
FR2938537B1 (fr) * | 2008-11-14 | 2012-10-26 | Sanofi Aventis | Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique. |
TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
FR2941696B1 (fr) * | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
CN102656172B (zh) | 2009-09-09 | 2016-03-23 | 大日本住友制药株式会社 | 8-氧代二氢嘌呤衍生物 |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
AU2011208418B2 (en) * | 2010-01-20 | 2016-01-07 | Sanofi | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application |
FR2955580A1 (fr) * | 2010-01-28 | 2011-07-29 | Sanofi Aventis | Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique |
US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
WO2010122178A2 (en) | 2010-05-25 | 2010-10-28 | Symrise Gmbh & Co. Kg | Cyclohexyl carbamate compounds as skin and/or hair lightening actives |
KR101778547B1 (ko) | 2010-05-25 | 2017-09-15 | 시므라이즈 아게 | 항-셀룰라이트 성분으로서의 사이클로헥실 카바메이트 화합물 |
EP2389922A1 (en) | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexyl carbamate compounds as anti-ageing actives |
JP5981429B2 (ja) * | 2010-07-28 | 2016-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 末梢に制限されたfaah阻害剤 |
EP2433527B1 (en) * | 2010-09-28 | 2013-04-03 | Gruppo Cimbali S.p.A. | Improved automatic milk frothing wand |
KR102079404B1 (ko) * | 2011-08-19 | 2020-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 메타-치환된 비페닐 말초 제한형 faah 억제제 |
WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
ITMI20131180A1 (it) | 2013-07-15 | 2015-01-16 | Fond Istituto Italiano Di Tecnologia | O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah) |
AR100387A1 (es) * | 2014-02-18 | 2016-10-05 | Basf Se | Copolímeros que comprenden etileno, ésteres de vinilo y ésteres de ácido (met)acrílico, sus formulaciones y usos como depresor del punto de fluidez, inhibidor de cera y potenciador de flujo para petróleos crudos |
EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
CA2987067A1 (en) * | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
TW201733620A (zh) | 2015-12-11 | 2017-10-01 | 國立大學法人靜岡大學 | 油凝膠化劑 |
US10220061B1 (en) | 2017-09-26 | 2019-03-05 | Cynthia Denapoli | Method of reducing stress and anxiety in equines |
US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE531554A (ru) * | 1953-09-02 | |||
US3084096A (en) * | 1955-08-29 | 1963-04-02 | Union Carbide Corp | Indanyl n-methyl carbamate |
US3275512A (en) | 1962-11-27 | 1966-09-27 | Upjohn Co | Process for treating inflammation with biphenylcarbamates |
US3632631A (en) | 1967-09-08 | 1972-01-04 | Ethyl Corp | Sterically hindered bisphenyl carbamates |
US3880908A (en) | 1972-01-24 | 1975-04-29 | Standard Oil Co | Urethane derivatives of polymethyl biphenyl useful as fungicides |
DE2943480A1 (de) * | 1979-10-27 | 1981-05-07 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von n,o-disubstituierten urethanen, sowie ihre verwendung als ausgangsmaterial zur herstellung von isocyanaten |
HU197831B (en) | 1984-12-20 | 1989-06-28 | Chinoin Gyogyszer Es Vegyeszet | Insecticide compositions containing alkenyl-oxy-phenyl-carbamat derivatives as active components and process for producing the active components |
IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
JPS63303661A (ja) | 1987-01-22 | 1988-12-12 | Ishikawajima Harima Heavy Ind Co Ltd | 注湯装置 |
US4987233A (en) | 1988-06-15 | 1991-01-22 | Eli Lilly And Company | Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives |
IL95994A0 (en) * | 1989-11-15 | 1991-07-18 | American Home Prod | Carbamate esters and pharmaceutical compositions containing them |
US5112859A (en) | 1990-09-14 | 1992-05-12 | American Home Products Corporation | Biphenyl amide cholesterol ester hydrolase inhibitors |
US5476944A (en) | 1991-11-18 | 1995-12-19 | G. D. Searle & Co. | Derivatives of cyclic phenolic thioethers |
US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5559410A (en) | 1992-12-17 | 1996-09-24 | Valeo Systemes D'essuyage | Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield |
US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
IT1271679B (it) * | 1994-07-18 | 1997-06-04 | Mediolanum Farmaceutici Srl | Derivati del fenilcarbammato atti all'impiego come anticolinesterasici |
DE4430600A1 (de) * | 1994-08-22 | 1996-02-29 | Hoechst Schering Agrevo Gmbh | Biphenyl-Derivate |
JPH0892167A (ja) * | 1994-09-21 | 1996-04-09 | Idemitsu Kosan Co Ltd | 芳香族炭酸ジエステルの製造方法 |
US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US6531506B1 (en) * | 1996-08-13 | 2003-03-11 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
SK64399A3 (en) * | 1996-11-19 | 2000-05-16 | Icn Pharmaceuticals | Multivalent salts of pyridostigmine and related compounds |
US5925672A (en) | 1996-12-06 | 1999-07-20 | Neurosciences Research Foundation, Inc. | Methods of treating mental diseases, inflammation and pain |
TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
US6251931B1 (en) | 1998-11-24 | 2001-06-26 | The Scripps Research Institute | Inhibitors of gap junction communication |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6359010B1 (en) * | 1999-11-23 | 2002-03-19 | Thomas D. Geracioti, Jr. | Methods of treating anxiety and mood disorders with oleamide |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
KR100613196B1 (ko) | 2000-07-19 | 2006-08-18 | 에프. 호프만-라 로슈 아게 | 메탈로프로테아제 억제제로서의 피롤리딘 유도체 |
FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
PL361783A1 (en) * | 2000-08-16 | 2004-10-04 | F.Hoffmann-La Roche Ag | Novel aminocyclohexane derivatives |
ES2275808T3 (es) | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
EP1389107A4 (en) * | 2001-04-27 | 2005-10-12 | Bristol Myers Squibb Co | BISARYLIMIDAZOLYL-FATTY ACID AMIDE-HYDROLASE INHIBITORS |
KR20040068240A (ko) | 2001-12-14 | 2004-07-30 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용 |
US6908939B2 (en) | 2001-12-21 | 2005-06-21 | Galderma Research & Development S.N.C. | Biaromatic ligand activators of PPARγ receptors |
WO2003065989A2 (en) | 2002-02-08 | 2003-08-14 | Bristol-Myers Squibb Company | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
UA80841C2 (en) * | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
-
2003
- 2003-10-07 UA UAA200504339A patent/UA80841C2/xx unknown
- 2003-10-07 US US10/681,858 patent/US7176201B2/en not_active Expired - Lifetime
- 2003-10-07 JP JP2004543510A patent/JP4515911B2/ja not_active Expired - Fee Related
- 2003-10-07 MX MXPA05003715A patent/MXPA05003715A/es unknown
- 2003-10-07 CA CA2501506A patent/CA2501506C/en not_active Expired - Fee Related
- 2003-10-07 EP EP03773201.3A patent/EP1558591B1/en not_active Expired - Lifetime
- 2003-10-07 EA EA200500615A patent/EA010267B1/ru not_active IP Right Cessation
- 2003-10-07 WO PCT/US2003/031844 patent/WO2004033422A2/en active Application Filing
- 2003-10-07 AU AU2003279877A patent/AU2003279877B2/en not_active Ceased
- 2003-10-07 KR KR1020057005995A patent/KR20050088992A/ko not_active Application Discontinuation
- 2003-10-07 CN CNB2003801052130A patent/CN100408556C/zh not_active Expired - Fee Related
-
2006
- 2006-07-28 US US11/496,051 patent/US8003693B2/en active Active
-
2011
- 2011-08-16 US US13/211,219 patent/US20120010283A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2693457C2 (ru) * | 2013-07-18 | 2019-07-03 | Фондацьоне Иституто Итальяно Ди Текнолоджия | Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr) |
Also Published As
Publication number | Publication date |
---|---|
MXPA05003715A (es) | 2005-09-30 |
JP2006511484A (ja) | 2006-04-06 |
CA2501506C (en) | 2014-02-11 |
US20120010283A1 (en) | 2012-01-12 |
EA010267B1 (ru) | 2008-06-30 |
US20090048337A1 (en) | 2009-02-19 |
AU2003279877B2 (en) | 2010-05-20 |
CN1729171A (zh) | 2006-02-01 |
US8003693B2 (en) | 2011-08-23 |
EP1558591A2 (en) | 2005-08-03 |
JP4515911B2 (ja) | 2010-08-04 |
KR20050088992A (ko) | 2005-09-07 |
US20040127518A1 (en) | 2004-07-01 |
WO2004033422A2 (en) | 2004-04-22 |
EP1558591A4 (en) | 2007-09-12 |
US7176201B2 (en) | 2007-02-13 |
CA2501506A1 (en) | 2004-04-22 |
WO2004033422A3 (en) | 2004-07-29 |
EP1558591B1 (en) | 2014-05-07 |
CN100408556C (zh) | 2008-08-06 |
AU2003279877A1 (en) | 2004-05-04 |
UA80841C2 (en) | 2007-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200500615A1 (ru) | Модуляция тревоги через блокаду гидролиза анандамида | |
TW200519088A (en) | Aryl or heteroaryl amide compounds | |
EP0343900A3 (en) | Piperazine compounds | |
CO5150173A1 (es) | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv | |
EA200600509A1 (ru) | Соединения пиримидотиофена | |
AR045255A1 (es) | Derivados de 1,2 benzodiazol | |
DE60127595D1 (de) | Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen | |
FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
TN2011000308A1 (fr) | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique | |
RU95122287A (ru) | Производные нипекотиновой кислоты как вещества, препятствующие тромбообразованию | |
MY139011A (en) | Piperazine compounds, a process for their preparation and pharmaceutical compositions containing them | |
ATE460425T1 (de) | Histondeacetylaseinhibitor und verfahren zu dessen herstellung | |
HUP0400207A2 (hu) | Helyettesített 4-amino-ciklohexanol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
EA200200665A1 (ru) | Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие | |
EA200200682A1 (ru) | Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие | |
EA200200733A1 (ru) | Новые гетероарильные производные, их получение и применение | |
CA2364199A1 (fr) | Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
DE602005017879D1 (de) | Nichtpeptidinhibitoren von matrixmetalloproteinasen | |
EA200000598A1 (ru) | Новые ингибиторы металлопротеазы, способ их получения и содержащие их фармацевтические композиции | |
ATE264840T1 (de) | Azetidincarboxamid-derivate zur behandlung von zns störungen | |
EA200100806A1 (ru) | Производные алкинилсодержащих гидроксамовых кислот, способы их получения и применение указанных веществ в качестве ингибиторов матриксной металлопротеиназы (ммр) и фно-альфа-конвертирующего фермента (tace) | |
DE69902142T2 (de) | Azetidincarboxamidderivate zur behandlung von zns-erkrankungen | |
ATE245155T1 (de) | N-substituierte 1-(butyrolacton)-isochinoline zur behandlung von nervenstörungen | |
EA199800470A1 (ru) | Производные фосфоновой кислоты, обладающие ингибирующей активностью в отношении металлопептидаз | |
SE9302437L (sv) | N-Derivat av (fenyletyl-beta-ol)amin, ett förfarande för deras framställning och läkemedelskompositioner som innehåller desamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |